Pliant Therapeutics Announces Positive Safety and Explorator

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , Toronto , Ontario , Canada , Krisv Kowdley , Gideon Hirshfield , Clin Gastroenterol Hepatol , Christopher Keenan , Terry Horner , Drug Administration , Youtube , European Medicines Agency , Clinical Development Next , University Of Toronto , Facebook , Pliant Therapeutics Inc , Linkedin , Liver Institute , Nasdaq , Corporate Communications , Enhanced Liver Fibrosis , Chief Medical Officer , Well Tolerated , Serious Adverse , Mayo Score , Demonstrated Antifibrotic Activity , Suspected Moderate , Severe Liver Fibrosis , Itch Numerical Rating Scale , Liver Institute Northwest , Washington State , Development Next , Primary Sclerosing , Terry Horner Chair , Autoimmune Liver Disease , Pliant Therapeutics , Fast Track Designation , Orphan Drug Designation , Private Securities Litigation Reform Act , Financial Condition , Quarterly Report , Media Contact , Investor Relations , Magn Reson ,